
North Dakota Medicaid Pharmacy Program Quarterly News

Published Quarterly by Health Information Designs, LLC

Welcome to the “North Dakota Medicaid Pharmacy Program Quarterly News,” a pharmacy newsletter presented by the North Dakota Department of Human Services and published by Health Information Designs, LLC. This newsletter is published as part of a continuing effort to keep the Medicaid provider community informed of important changes in the North Dakota Medicaid Pharmacy Program.

The North Dakota Department of Human Services has contracted with Health Information Designs, LLC (HID) to review and process prior authorizations (PAs) for medications. For a current list of medications requiring a PA, as well as the necessary forms and criteria, visit www.hidndmedicaid.com, or call HID at (866) 773-0695 to have this information faxed. An important feature on this website is the NDC Drug Lookup. This allows you to determine if a specific NDC is covered (effective date), reimbursement amount, MAC pricing, copay information, and any limitations (prior authorization or quantity limits).

This newsletter provides information regarding significant new dosage forms introduced in 2012. Also included is the top 25 drug list of second quarter 2012 by cost and claims count.

The North Dakota Medicaid Pharmacy Program team appreciates your comments and suggestions regarding this newsletter. To suggest topics for inclusion, or to make comments, please contact Health Information Designs, LLC at (334) 502-3262, call toll free at 1-800-225-6998, or e-mail us at info@hidinc.com.



Helpful Numbers

PA Help Desk 866-773-0695
To fax PAs 866-254-0761
To report adverse reactions 800-FDA-1088

Inside this issue:	Page
Welcome	1
Helpful Numbers	1
Significant New Dosage Forms-2012	2
Top 25 by Cost and Claims Count	3
Health Information Designs, LLC	4

Visit HID's North Dakota Department of Human Services Prior Authorization Webpage, www.hidndmedicaid.com.

Significant New Dosage Forms - 2012

Brand/Generic	Description
Absorica (isotretinoin)	New formulation for severe recalcitrant nodular acne.
Adasuve (loxapine)	New oral inhalation formulation for acute treatment of agitation associated with schizophrenia or bipolar I disorder.
Afinitor Disperz (everolimus)	New tablets for oral suspension formulation for pediatric use.
Asthmanefrin (raccipinephrine)	An OTC non-CFC inhaler for mild asthma.
Bethkis (tobramycin)	New concentration inhalation solution for cystic fibrosis patients with <i>Pseudomonas aeruginosa</i> .
Binosto (alendronate)	New effervescent tablet formulation for osteoporosis.
Bydureon (exenatide)	An extended-release injectable suspension for type 2 diabetes.
Cosopt PF (dorzolamide/timolol)	New preservative-free, single-use ophthalmic solution for glaucoma or ocular hypertension.
Cystaran (cysteamine)	New ophthalmic formulation for patients with cystinosis.
Dymista (azelastine/fluticasone)	New combination antihistamine and steroid nasal spray for seasonal allergic rhinitis.
Fabior (tazarotene)	New topical foam retinoid for treatment of acne.
Giazo (balsalazide)	New strength and tablet formulation for ulcerative colitis in males.
Janumet XR (sitagliptin/metformin)	An extended-release formulation for type 2 diabetes.
Jentaduetto (linagliptin/metformin)	New combination formulation for type 2 diabetes.
Korlym (mifepristone)	A cortisol receptor blocker to control hyperglycemia in patients with endogenous Cushing's syndrome.
Lupaneta Pack (leuprolide/norethindrone)	New combination gonadotropin-releasing hormone analog and progestin formulation.
Marqibo (vincristine)	New liposome formulation for Philadelphia chromosome-negative acute lymphoblastic leukemia.
Minivelle (estradiol)	New transdermal patch for menopausal vasomotor symptoms.
Mitosol (mitomycin)	A topical solution for use during glaucoma filtration surgery.
Nucynta (tapentadol)	New oral solution formulation for moderate-severe acute pain.
Onfi (clobazam)	New oral suspension formulation for seizures associated with Lennox-Gastaut syndrome.
Oxtellar XR (oxcarbazepine)	A new extended-release formulation for partial seizures.
Pertzye (pancrelipase)	FDA-approved version of a previously marketed 'unapproved' drug.
Qnasl (beclomethasone)	A new dry powder formulation for allergic rhinitis.
Qsymia (phentermine/topiramate)	New combination formulation for chronic weight management.
Quillivant XR (methylphenidate)	An extended-release oral suspension for ADHD.
Rayos (prednisone)	New delayed-release tablet formulation.
Sklice (ivermectin)	A topical lotion formulation for head lice.
Subsys (fentanyl)	New sublingual spray formulation for breakthrough cancer pain.
Suprenza (phentermine)	New orally disintegrating tablet for weight loss.
Ultresa (pancrelipase)	An FDA-approved version of a previously marketed 'unapproved' drug.
Viokace (pancrelipase)	An FDA-approved version of a previously marketed 'unapproved' drug.
Viread (tenofovir)	New oral powder formulation for HIV-1 or chronic hepatitis B infections.
Ximino (minocycline)	An extended-release capsule formulation for inflammatory moderate to severe acne.
Zetonna (ciclesonide)	A lower strength nasal spray formulation for allergic rhinitis.

Top 25 Drugs for 2nd Quarter 2012

Top 25 Drugs by Number of Claims			Top 25 Drugs by Total Claims Cost		
Drug	Claims Count	Paid Amount	Drug	Claims Count	Paid Amount
HYDROCOD-APAP	4,762	\$62,620.12	ABILIFY	862	\$436,845.91
LORAZEPAM	3,975	\$31,765.19	METHYLPHENIDATE ER	2,324	\$331,220.25
AMOXICILLIN	3,534	\$39,247.52	SINGULAIR	1,974	\$293,619.18
AZITHROMYCIN	2,999	\$50,876.86	CYMBALTA	1,103	\$201,195.38
OMEPRAZOLE	2,893	\$43,570.77	VYVANSE	1,518	\$198,562.78
CLONAZEPAM	2,850	\$21,373.89	DEXTROAM-PHETAMINE-AMPH	1,254	\$198,155.20
PROVENTIL HFA	2,593	\$135,256.25	ADVAIR DISKUS	722	\$171,225.16
METHYLPHENIDATE ER	2,324	\$331,220.25	PROVENTIL HFA	2,593	\$135,256.25
TRAMADOL HCL	2,065	\$25,013.94	NOVOLOG	510	\$127,138.99
LEVOTHYROXINE	2,051	\$22,750.17	LYRICA	707	\$125,850.22
SERTRALINE	2,017	\$19,082.05	INTUNIV	941	\$124,225.32
SINGULAIR	1,974	\$293,619.18	BUDESONIDE	520	\$120,554.35
FLUOXETINE HCL	1,867	\$13,568.11	FREESTYLE STRIPS	968	\$112,477.51
TRAZODONE HCL	1,712	\$12,560.08	STRATTERA	628	\$111,038.73
LISINOPRIL	1,683	\$13,720.80	SEROQUEL XR	307	\$101,069.89
ALPRAZOLAM	1,664	\$14,216.25	ENBREL	43	\$94,180.19
VYVANSE	1,518	\$198,562.78	LANTUS SO-LOSTAR	409	\$93,635.78
GABAPENTIN	1,422	\$37,929.62	METADATE CD	572	\$88,658.86
ZOLPIDEM TARTRATE	1,415	\$11,501.07	ENOXAPARIN	102	\$86,340.43
RISPERIDONE	1,387	\$18,524.76	OLANZAPINE	379	\$79,720.79
CYCLOBENZAPRINE	1,364	\$11,137.49	HELIXATE FS	3	\$78,630.30
CLONIDINE HCL	1,359	\$10,825.91	LEVEMIR	313	\$77,983.35
SULFAMETHOX-TRIMETHOPRIM	1,339	\$15,243.90	INVEGA	127	\$77,768.61
METFORMIN HCL	1,315	\$14,209.03	ESCITALOPRAM	879	\$77,062.83
BUPROPION XL	1,298	\$36,161.46	INVEGA SUSTENNA	58	\$74,442.72
TOTAL TOP 25 BY CLAIMS COUNT	53,380	\$1,484,557.45	TOTAL TOP 25 BY CLAIMS COST	19,816	\$3,616,858.98



Health Information Designs, LLC is the most experienced and qualified provider of drug utilization review and pharmacy support services in the country. We specialize in helping our clients promote clinically appropriate and cost-effective prescribing, dispensing, and utilization of prescription drugs.

Health Information Designs, LLC was founded in 1976 with a mission to improve patient care and contain costs for state Medicaid agencies by providing drug utilization review (DUR) services. In 1997, HID was acquired by HDI Solutions and subsequently has experienced strong and steady growth as a premium healthcare analytics and pharmacy support services provider. HID is the industry leader in providing comprehensive prescription drug monitoring programs. Currently, HID works with clients in 30 states, including 16 Medicaid agencies, 22 Boards of Pharmacy and state health agencies, and several private healthcare benefit management organizations. The work performed by HID has a daily impact on the healthcare of more than 115 million Americans.

HEALTH
INFORMATION DESIGNS

391 Industry Drive
Auburn, AL 36832
Tel: 800-748-0130
Fax: 800-748-0116

PRST STD
U.S. Postage